Biophan CEO Discusses Biomedical Device Breakthroughs with Medical Design Technology Magazine Available Online; CEO Michael Weiner Interviewed with Other Medical Device Industry Leaders.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, announced that CEO Michael Weiner discussed the Company's proprietary solutions for the multi-billion-dollar medical device industry in an interview with industry magazine "Medical Design Technology." The full text of the interview, which includes comments from several leaders in the medical device industry, can be read online by visiting http://www.biophan.com/newsroom.php and clicking on the article, "Key Trends and Issues."

In a special feature titled, "Key Trends and Issues," in the magazine's View from the Top article series, Mr. Weiner and other selected business and technology leaders offer insights about important trends and innovations in the medical device industry. They discussed recent advancements in the industry, the latest techniques in manufacturing, anticipated growth sectors, and technologies with the greatest growth potential in the next five years.

Mr. Weiner discussed areas in which Biophan is developing innovations, including the Company's proprietary MRI-enabling technologies for pacemakers, defibrillators, neurostimulators, stents, vena cava filters, catheters, guidewires, drug pumps and other devices.

"The ability to make medical devices both safe and image-compatible with MRI is beginning to alter the way devices are being designed for future manufacturing," Mr. Weiner says in the article. "This is a wide swath of the medical device landscape from neurological devices that can now allow functional MRI of post-procedure patients to MRI-safe pacemakers, defibrillators, and neurostimulators, as well as image compatible stents and vena cava filters that can be diagnosed for in-stent restenosis or thrombosis non-invasively using via MRI."

In addition to Mr. Weiner, other experts interviewed include Bruce Barclay, president and CEO of SurModics Inc. (NASDAQ: SRDX); George W. Blank, president of The MedTech Group Inc.; Ron Earle, recently retired group senior vice president of B. Braun Medical Inc.'s OEM/Industrial Division; Suchit Jain, vice president of analysis products at SolidWorks Corp.; Kay Phillips, president of ATEK Medical Manufacturing; and FDA's CDRH Director Dr. Dan Schultz, who shares his thoughts on key challenges for his agency.

About Medical Design Technology

Medical Design Technology keeps the medical device manufacturing industry up to date with the latest developments in this growing and increasingly competitive field. Medical Design Technology reaches 35,000 design engineers, engineering managers and other important industry professionals, each qualified by job function, business and industry. For more information, please visit http://www.mdtmag.com/scripts/default.asp

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat and optical catheter technologies. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.